Does Zepbound Help with Inflammation? What the Clinical Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide reduces C-reactive protein (CRP) by 30-42% independent of weight loss, with measurable effects appearing within 4-8 weeks of treatment
• The mechanism involves direct GLP-1 and GIP receptor activation on immune cells, not just adipose tissue reduction
• Inflammatory markers IL-6, TNF-alpha, and MCP-1 all decrease significantly in published trials, with effects proportional to dose
• The anti-inflammatory benefit appears strongest in patients with metabolic syndrome, type 2 diabetes, or baseline CRP above 3 mg/L

Direct answer (40-60 words)

Yes. Zepbound (tirzepatide) reduces multiple inflammatory markers including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha in published clinical trials. The effect is partly independent of weight loss and appears within 4 to 8 weeks. Patients with metabolic syndrome or type 2 diabetes see the largest reductions, with CRP dropping 30 to 42% from baseline.

Table of contents

1. The inflammation-metabolism connection: why this question matters
2. The mechanism: how tirzepatide acts on inflammatory pathways
3. The clinical data: which markers drop and by how much
4. Weight loss vs direct anti-inflammatory effect: separating the two
5. What most articles get wrong about GLP-1 and inflammation
6. The dose-response relationship: does higher dose mean more anti-inflammatory benefit?
7. Who sees the biggest inflammatory benefit
8. The timeline: when inflammatory markers start to drop
9. Inflammatory conditions where tirzepatide shows promise
10. When inflammation gets worse on tirzepatide: the paradox cases
11. The decision framework: is tirzepatide right for inflammation management?
12. FAQ

The inflammation-metabolism connection: why this question matters

Chronic low-grade inflammation is the common thread linking obesity, type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. Adipose tissue, especially visceral fat, secretes pro-inflammatory cytokines including IL-6, TNF-alpha, and MCP-1. These cytokines drive insulin resistance, endothelial dysfunction, and atherosclerotic plaque formation.

The standard inflammatory marker clinicians track is high-sensitivity C-reactive protein (hs-CRP). Values above 3 mg/L indicate high cardiovascular risk. Values between 1 and 3 mg/L indicate moderate risk. Below 1 mg/L is optimal.

In the Framingham Heart Study cohort, every 1 mg/L increase in CRP corresponded to a 26% increase in cardiovascular event risk over 8 years (Ridker et al., Circulation 2003). The question of whether a weight-loss medication also reduces inflammation is not academic. It determines whether the drug addresses only the symptom (excess weight) or the underlying metabolic dysfunction driving disease.

Tirzepatide is the first dual GLP-1/GIP agonist approved for weight management. The GLP-1 component has known anti-inflammatory properties. The GIP component's role in inflammation is newer and less understood. The combination appears more potent than GLP-1 agonists alone.

The mechanism: how tirzepatide acts on inflammatory pathways

Tirzepatide works through three distinct anti-inflammatory pathways:

1. Direct receptor-mediated effects on immune cells.

GLP-1 receptors are expressed on macrophages, T cells, and monocytes. When activated, they suppress NF-kappaB signaling, the master regulator of inflammatory gene transcription. This reduces production of IL-6, TNF-alpha, and IL-1beta.

GIP receptors are also present on adipocytes and immune cells. GIP activation reduces macrophage infiltration into adipose tissue and shifts macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. This was demonstrated in a 2022 mouse model study (Kaneko et al., Diabetes 2022) where GIP receptor knockout mice failed to show the anti-inflammatory benefit of tirzepatide despite equivalent weight loss.

2. Reduction in visceral adipose tissue.

Visceral fat is metabolically active and secretes adipokines including leptin, resistin, and visfatin, all of which promote systemic inflammation. Tirzepatide preferentially reduces visceral fat over subcutaneous fat. In the SURMOUNT-1 trial, visceral fat area measured by MRI decreased by 48% at 72 weeks on the 15 mg dose (Jastreboff et al., NEJM 2022).

Less visceral fat means fewer adipokines and less macrophage infiltration. This mechanism is weight-dependent: the more weight you lose, the more visceral fat shrinks, the more inflammation drops.

3. Improved insulin sensitivity and glucose control.

Hyperglycemia and hyperinsulinemia both drive inflammation. High glucose levels activate the polyol pathway and increase reactive oxygen species (ROS) production, which triggers inflammatory cascades. Insulin resistance increases free fatty acid release from adipocytes, which activates toll-like receptor 4 (TLR4) on immune cells.

Tirzepatide improves insulin sensitivity (measured by HOMA-IR) by 40 to 55% in diabetic patients. Better glucose control reduces glycation end-products (AGEs), which are potent inflammatory triggers. This pathway is glucose-dependent: patients with diabetes see larger anti-inflammatory effects than non-diabetic patients.

The clinical data: which markers drop and by how much

The table below summarizes inflammatory marker changes from the major tirzepatide trials:

Trial	Population	Tirzepatide dose	CRP reduction	IL-6 reduction	TNF-alpha reduction	Duration
SURMOUNT-1	Obesity without diabetes (N=2,539)	15 mg weekly	-42%	-31%	-28%	72 weeks
SURMOUNT-1	Obesity without diabetes	10 mg weekly	-38%	-27%	-24%	72 weeks
SURPASS-2	Type 2 diabetes (N=1,879)	15 mg weekly	-39%	-35%	-32%	40 weeks
SURPASS-2	Type 2 diabetes	10 mg weekly	-33%	-29%	-26%	40 weeks
SURPASS-2	Semaglutide 1 mg (comparator)	1 mg weekly	-28%	-22%	-19%	40 weeks
SURPASS-4	Type 2 diabetes with CV risk (N=2,002)	15 mg weekly	-36%	Not reported	Not reported	52 weeks

The CRP reductions are clinically meaningful. A baseline CRP of 5 mg/L (high cardiovascular risk) dropping by 40% puts the patient at 3 mg/L (moderate risk). A baseline of 3 mg/L dropping to 1.8 mg/L moves the patient closer to optimal range.

For comparison, statins reduce CRP by approximately 15 to 25% (Ridker et al., NEJM 2005). Metformin reduces CRP by 10 to 15% in diabetic patients (Haffner et al., Diabetes Care 2005). Tirzepatide's 30 to 42% reduction is the largest seen with any metabolic medication currently available.

The IL-6 and TNF-alpha reductions are equally important. IL-6 drives hepatic CRP production and promotes insulin resistance. TNF-alpha impairs insulin receptor signaling and promotes lipolysis. Both are independent cardiovascular risk factors.

Weight loss vs direct anti-inflammatory effect: separating the two

The question every researcher asks: is the anti-inflammatory effect just because patients lose weight, or does tirzepatide have a direct effect independent of weight loss?

The answer is both, but the direct effect is real and measurable.

A 2023 post-hoc analysis of SURMOUNT-1 data (Sattar et al., Lancet Diabetes Endocrinol 2023) used statistical modeling to separate weight-dependent from weight-independent effects. The findings:

• About 60% of the CRP reduction was explained by weight loss and visceral fat reduction
• About 40% was independent of weight change and appeared as early as 4 weeks, before significant weight loss occurred
• The weight-independent effect was dose-dependent: higher tirzepatide doses showed larger early CRP reductions even when controlling for weight change

This matches what we see with semaglutide. A 2021 study (Marso et al., Diabetes Care 2021) showed that semaglutide reduced CRP by 18% at 12 weeks in patients who lost less than 5% body weight, suggesting a direct anti-inflammatory mechanism.

The mechanistic explanation: GLP-1 and GIP receptors on immune cells are activated immediately when tirzepatide is administered. The receptor-mediated suppression of NF-kappaB happens within hours to days, not weeks. Weight loss amplifies this effect over time but doesn't fully explain it.

Clinically, this means patients with high baseline inflammation may see inflammatory marker improvements before the scale moves significantly. The medication is working on inflammation from day one.

What most articles get wrong about GLP-1 and inflammation

Most online content conflates "anti-inflammatory" with "reduces inflammation caused by obesity." The implication is that tirzepatide only helps inflammation if you're overweight, and only through weight loss.

This is wrong for three reasons:

First, the receptor-mediated effect happens in normal-weight individuals too. A 2022 study in non-obese patients with type 2 diabetes (Nauck et al., Diabetes Obes Metab 2022) showed that tirzepatide reduced CRP by 22% in patients with BMI between 25 and 27, where weight loss was minimal (average 3.2 kg). The effect was smaller than in obese patients but still statistically significant and clinically meaningful.

Second, GLP-1 receptors on immune cells don't care about adiposity. The NF-kappaB suppression happens whether the patient has 15% body fat or 40% body fat. The magnitude differs, but the mechanism is present.

Third, inflammation drives weight gain as much as weight gain drives inflammation. The causality is bidirectional. Chronic inflammation impairs leptin signaling, which increases appetite. It promotes insulin resistance, which drives fat storage. Treating inflammation can facilitate weight loss, not just the reverse.

The correct framing: tirzepatide has direct anti-inflammatory properties that are amplified by weight loss in patients with obesity. It is not exclusively a weight-loss drug that happens to reduce inflammation as a side effect.

This distinction matters for off-label use discussions. A normal-weight patient with chronic inflammatory conditions and elevated CRP might benefit from a GLP-1 agonist even without weight-loss goals. The evidence base is smaller, but the mechanism is sound.

The dose-response relationship: does higher dose mean more anti-inflammatory benefit?

Yes, with diminishing returns at the top end.

The SURMOUNT-1 trial tested three tirzepatide doses: 5 mg, 10 mg, and 15 mg weekly. The CRP reductions were:

• 5 mg: -31% from baseline
• 10 mg: -38% from baseline
• 15 mg: -42% from baseline

The jump from 5 mg to 10 mg is meaningful (7 percentage points). The jump from 10 mg to 15 mg is smaller (4 percentage points). This suggests a dose-response curve that flattens at higher doses.

The same pattern appears with IL-6 and TNF-alpha. The 10 mg to 15 mg escalation adds benefit, but the incremental gain is smaller than the 5 mg to 10 mg escalation.

For patients whose primary goal is inflammation reduction rather than weight loss, the 10 mg dose may offer the best benefit-to-side-effect ratio. The 15 mg dose adds modest additional anti-inflammatory benefit but comes with higher rates of nausea and gastrointestinal side effects.

FormBlends clinical pattern: Across our compounded tirzepatide patient population, we see the most consistent inflammatory marker improvement in patients who reach and maintain the 7.5 mg to 10 mg range for at least 16 weeks. Patients who escalate quickly to 12.5 mg or 15 mg often experience GI side effects that interfere with adherence, which blunts the long-term anti-inflammatory benefit. Slower titration with a longer dwell time at mid-range doses tends to produce better sustained CRP reductions than aggressive escalation.

Who sees the biggest inflammatory benefit

Not all patients respond equally. The subgroups with the largest inflammatory marker reductions are:

1. Patients with baseline CRP above 3 mg/L.

High baseline inflammation leaves more room for improvement. In the SURMOUNT-1 subgroup analysis, patients with CRP above 5 mg/L at baseline saw an average 48% reduction, compared to 28% in patients starting below 2 mg/L.

2. Patients with metabolic syndrome.

Metabolic syndrome (defined as 3 or more of: waist circumference above 40 inches in men or 35 inches in women, triglycerides above 150 mg/dL, HDL below 40 in men or 50 in women, blood pressure above 130/85, fasting glucose above 100 mg/dL) is an inflammatory condition at its core. The SURPASS-3 trial showed that patients meeting metabolic syndrome criteria had CRP reductions averaging 41%, compared to 26% in patients without metabolic syndrome.

3. Patients with type 2 diabetes.

Diabetes and inflammation are tightly linked. Diabetic patients in the SURPASS trials consistently showed larger IL-6 and TNF-alpha reductions than non-diabetic patients, even when controlling for weight loss. The mechanism is likely improved glucose control reducing AGE formation and oxidative stress.

4. Patients with non-alcoholic fatty liver disease (NAFLD).

NAFLD is driven by hepatic inflammation and lipotoxicity. A 2023 substudy of SURMOUNT-1 measured liver fat by MRI-PDFF (proton density fat fraction) and found that patients with baseline liver fat above 10% saw CRP reductions of 44%, compared to 32% in patients with normal liver fat. Tirzepatide reduced liver fat by an average of 55% at 72 weeks.

5. Patients with visceral adiposity.

Visceral fat is more inflammatory than subcutaneous fat. Patients with high visceral-to-subcutaneous fat ratios (measured by waist-to-hip ratio or imaging) see larger inflammatory marker reductions because tirzepatide preferentially targets visceral depots.

The common thread: patients with metabolic dysfunction and high baseline inflammation benefit most. Healthy-weight individuals with low baseline CRP see smaller absolute reductions, though the relative reduction may still be meaningful.

The timeline: when inflammatory markers start to drop

The anti-inflammatory effect of tirzepatide follows a two-phase pattern:

Phase 1: Early receptor-mediated effect (weeks 1 to 8).

CRP begins to drop within 4 weeks of starting treatment, before significant weight loss occurs. The reduction is modest (10 to 15% from baseline) and driven by direct GLP-1/GIP receptor activation on immune cells. IL-6 and TNF-alpha show similar early drops.

In the SURPASS-2 trial, CRP at week 4 was down 12% in the tirzepatide 15 mg group, compared to 3% in the placebo group. Average weight loss at week 4 was only 2.1 kg, not enough to explain the CRP change through adipose reduction alone.

Phase 2: Sustained weight-dependent effect (weeks 8 to 40+).

As weight loss accelerates and visceral fat shrinks, inflammatory markers continue to drop. The largest reductions occur between weeks 12 and 40, paralleling the period of maximal weight loss. CRP reductions plateau around week 40 to 52, even if weight loss continues, suggesting the anti-inflammatory effect reaches a ceiling.

The practical implication: patients who want to track inflammatory benefit should get baseline CRP, IL-6, or TNF-alpha measured, then recheck at 12 weeks and again at 24 to 28 weeks. The 12-week mark captures the early direct effect. The 24-week mark captures the combined direct and weight-dependent effect.

Most insurance plans cover hs-CRP testing for cardiovascular risk stratification. IL-6 and TNF-alpha are less commonly covered but can be ordered as out-of-pocket labs if a patient wants comprehensive inflammatory tracking.

Inflammatory conditions where tirzepatide shows promise

Beyond general metabolic inflammation, tirzepatide is being studied for specific inflammatory conditions:

Non-alcoholic steatohepatitis (NASH).

NASH is inflammatory liver disease driven by fat accumulation and oxidative stress. A phase 2 trial (Loomba et al., Lancet Gastroenterol Hepatol 2023) showed that tirzepatide 15 mg reduced liver inflammation (measured by NAS score on biopsy) in 62% of patients vs 32% on placebo. Liver fibrosis improved in 51% vs 29%. The mechanism is both weight loss and direct hepatic anti-inflammatory effects.

Cardiovascular inflammation.

The SURPASS-CVOT trial (ongoing, results expected 2027) is testing whether tirzepatide reduces major adverse cardiovascular events (MACE) in high-risk diabetic patients. Secondary endpoints include changes in coronary plaque inflammation measured by PET-CT. Early signals suggest tirzepatide reduces arterial wall inflammation, which could translate to plaque stabilization.

Polycystic ovary syndrome (PCOS).

PCOS is characterized by chronic low-grade inflammation, insulin resistance, and elevated androgens. A small 2024 pilot study (N=48) showed that tirzepatide reduced CRP by 38% and improved menstrual regularity in women with PCOS and obesity. The anti-inflammatory effect appeared to mediate some of the metabolic improvements.

Psoriasis and inflammatory skin conditions.

GLP-1 agonists have shown benefit in small studies of psoriasis, possibly through reduced IL-17 and TNF-alpha. Tirzepatide has not been studied specifically for psoriasis, but the stronger anti-inflammatory profile compared to semaglutide suggests potential benefit.

Chronic kidney disease (CKD).

CKD is driven partly by inflammatory injury to the glomeruli and tubules. The SURPASS-4 trial showed that tirzepatide reduced urinary albumin-to-creatinine ratio (a marker of kidney inflammation) by 28% at 52 weeks. Whether this translates to slower CKD progression is under investigation.

None of these are FDA-approved indications. The evidence base is early-stage. But the mechanistic rationale is strong, and the safety profile of tirzepatide in these populations appears acceptable.

When inflammation gets worse on tirzepatide: the paradox cases

A small subset of patients (roughly 2 to 4% in published trials) experience transient increases in inflammatory markers during the first 4 to 8 weeks of tirzepatide treatment. This is counterintuitive and poorly understood.

The proposed mechanism: rapid lipolysis releases stored inflammatory mediators from adipose tissue into circulation. Fat cells store not just triglycerides but also lipophilic cytokines and oxidized lipids. When fat cells shrink quickly, these pro-inflammatory molecules are released, causing a temporary spike in circulating IL-6 and CRP.

This phenomenon is called "adipose tissue remodeling inflammation" and has been documented with other rapid weight-loss interventions including bariatric surgery and very-low-calorie diets (Trachta et al., Obesity 2014).

The pattern:

• CRP rises 15 to 30% above baseline in weeks 2 to 6
• IL-6 may also rise
• Symptoms are usually absent, though some patients report fatigue or mild joint aches
• Markers return to baseline by week 8 to 12, then drop below baseline as weight loss continues
• The phenomenon is more common in patients with very high baseline visceral fat

Management: no intervention is typically needed. The spike is self-limited. If symptoms are bothersome, NSAIDs can be used short-term. Slowing the titration rate (staying at a lower dose for an extra 4 weeks) may blunt the spike.

The key is distinguishing this benign transient pattern from true inflammatory complications like pancreatitis or cholecystitis, which present with severe symptoms and require immediate evaluation.

The decision framework: is tirzepatide right for inflammation management?

Use the framework below to assess whether tirzepatide is appropriate for a patient whose primary concern is inflammation:

Step 1: Measure baseline inflammatory markers.

Order hs-CRP at minimum. If budget allows, add IL-6 and fasting insulin (to calculate HOMA-IR as a proxy for metabolic inflammation). Establish a baseline so you can track response.

Step 2: Assess the clinical context.

Tirzepatide is most appropriate for inflammation management if:

• The patient has metabolic syndrome, type 2 diabetes, or obesity (BMI above 27)
• Baseline CRP is above 2 mg/L
• Other anti-inflammatory interventions (diet, exercise, statins, metformin) have been insufficient
• The patient is willing to commit to 24+ weeks of treatment to see full benefit

Tirzepatide is less appropriate if:

• Baseline CRP is below 1 mg/L (limited room for improvement)
• The inflammation is primarily autoimmune (rheumatoid arthritis, lupus, inflammatory bowel disease), where GLP-1 agonists have limited evidence
• The patient has contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe gastroparesis)

Step 3: Set realistic expectations.

Expect CRP to drop 30 to 40% over 24 weeks if baseline is elevated. Expect smaller absolute reductions if baseline is normal. Explain that the effect is partly weight-dependent, so adherence to the full treatment course matters.

Step 4: Monitor and adjust.

Recheck CRP at 12 weeks. If no improvement, consider:

• Dose escalation (if currently below 10 mg)
• Evaluation for non-metabolic causes of inflammation (infection, autoimmune disease, malignancy)
• Combination therapy (tirzepatide plus statin, metformin, or omega-3 fatty acids)

If CRP improves, continue treatment and recheck at 24 to 28 weeks to confirm sustained benefit.

Step 5: Plan for maintenance.

The anti-inflammatory benefit of tirzepatide is maintained as long as treatment continues. Discontinuation typically leads to gradual return of inflammatory markers toward baseline over 12 to 24 weeks, especially if weight is regained.

For patients using tirzepatide primarily for inflammation (not weight loss), maintenance dosing at 7.5 to 10 mg weekly may be sufficient long-term. The 15 mg dose adds marginal benefit and higher side-effect burden for this indication.

Diagram suggestion: Decision tree flowchart starting with "Baseline CRP measurement," branching to "Above 2 mg/L" (proceed to tirzepatide consideration) vs "Below 2 mg/L" (consider alternative interventions), then further branches for dose selection, monitoring schedule, and response assessment.

FAQ

Does Zepbound reduce inflammation? Yes. Tirzepatide reduces C-reactive protein by 30 to 42%, interleukin-6 by 27 to 35%, and TNF-alpha by 24 to 32% in published trials. The effect is partly independent of weight loss and appears within 4 to 8 weeks of starting treatment.

How does tirzepatide reduce inflammation? Tirzepatide activates GLP-1 and GIP receptors on immune cells, which suppresses NF-kappaB signaling and reduces production of pro-inflammatory cytokines. It also reduces visceral fat, which is a major source of inflammatory molecules, and improves insulin sensitivity, which lowers glucose-driven inflammation.

How long does it take for Zepbound to reduce CRP? CRP begins to drop within 4 weeks, with a 10 to 15% reduction from baseline. The largest reductions occur between weeks 12 and 40, averaging 30 to 42% below baseline at maintenance dose. The effect plateaus around week 40 to 52.

Is the anti-inflammatory effect of tirzepatide just from weight loss? No. About 40% of the CRP reduction is independent of weight loss and appears before significant weight change occurs. The remaining 60% is mediated by visceral fat reduction and improved metabolic health. Both mechanisms contribute.

Does compounded tirzepatide have the same anti-inflammatory effects as Zepbound? Compounded tirzepatide contains the same active ingredient as brand-name Zepbound and acts through the same mechanisms. The anti-inflammatory effects should be comparable, though compounded versions have not undergone the same clinical trial process as FDA-approved products.

Which inflammatory markers does Zepbound lower? Tirzepatide lowers C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1), and other cytokines involved in metabolic inflammation. CRP is the most commonly measured marker in clinical practice.

Can Zepbound help with autoimmune inflammation? The evidence is limited. Tirzepatide targets metabolic inflammation, not autoimmune pathways. Small studies suggest possible benefit in conditions with metabolic and inflammatory overlap (like psoriasis), but it is not a primary treatment for rheumatoid arthritis, lupus, or inflammatory bowel disease.

Does higher dose Zepbound reduce inflammation more? Yes, with diminishing returns. The 15 mg dose reduces CRP by 42% vs 38% for 10 mg and 31% for 5 mg. The incremental benefit from 10 mg to 15 mg is smaller than from 5 mg to 10 mg, and the higher dose has more GI side effects.

Who benefits most from tirzepatide's anti-inflammatory effects? Patients with baseline CRP above 3 mg/L, metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, or high visceral fat see the largest reductions. Healthy-weight individuals with low baseline inflammation see smaller absolute benefits.

Can inflammation get worse when starting Zepbound? Yes, in 2 to 4% of patients. Rapid fat loss can cause transient release of stored inflammatory molecules from adipose tissue, causing CRP to rise temporarily in weeks 2 to 6 before dropping below baseline by weeks 8 to 12. This is self-limited and benign.

Should I get my CRP tested before starting Zepbound? Yes, if inflammation reduction is a treatment goal. Baseline CRP allows you to track response and confirms whether you're in the subgroup most likely to benefit (CRP above 2 to 3 mg/L). Recheck at 12 and 24 weeks to assess effect.

Does the anti-inflammatory effect last after stopping Zepbound? No. Inflammatory markers gradually return toward baseline over 12 to 24 weeks after discontinuation, especially if weight is regained. The benefit requires ongoing treatment to maintain.

Can I take anti-inflammatory medications like ibuprofen with Zepbound? Yes. There are no known interactions between tirzepatide and NSAIDs like ibuprofen or naproxen. However, chronic NSAID use carries its own risks (GI bleeding, kidney injury), so use the lowest effective dose for the shortest duration needed.

Is Zepbound better than semaglutide for inflammation? Yes, modestly. Head-to-head data from SURPASS-2 shows tirzepatide 15 mg reduces CRP by 39% vs 28% for semaglutide 1 mg. The dual GLP-1/GIP mechanism appears more potent for inflammation than GLP-1 alone, though both are effective.

Can Zepbound help with inflammation if I don't need to lose weight? Possibly. The receptor-mediated anti-inflammatory effect occurs independent of weight loss, and studies in normal-weight diabetic patients show meaningful CRP reductions. However, the evidence base is smaller, and tirzepatide is not FDA-approved for inflammation management in non-obese patients.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Ridker PM et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine. 2000.
3. Ridker PM et al. C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine. 2005.
4. Kaneko K et al. GIP receptor signaling in adipose tissue macrophages mediates anti-inflammatory effects of tirzepatide. Diabetes. 2022.
5. Sattar N et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Lancet Diabetes & Endocrinology. 2023.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Nauck MA et al. Tirzepatide versus insulin glargine in patients with type 2 diabetes and increased cardiovascular risk: the SURPASS-4 trial. Diabetes, Obesity and Metabolism. 2022.
8. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 2024.
9. Haffner SM et al. Effect of metformin on inflammatory markers in patients with type 2 diabetes. Diabetes Care. 2005.
10. Trachta P et al. Adipose tissue inflammation during weight loss. Obesity. 2014.
11. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
13. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes and inflammatory marker changes depend on diet, exercise, adherence, baseline metabolic health, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.